Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
活動性強直性脊椎炎患者におけるbimekizumabの安全性と 有効性: フェーズIIb無作為化対照試験とそのオープンラベル延長試験 からの3年結果
Arthritis Rheumatol. 2022;74:1943–58
In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.
Keywords:
活動性強直性脊椎炎患者におけるビメキズマブの安全性と有効性: フェーズ2b 無作為化対照試験とそのオープンラベル試験の3年結果
Arthritis Rheumatol 2022 doi: 10.1002/art.42282
Bimekizumab is associated with sustained, long-term efficacy in r-axSpA patinets across three years of treatment. In coming to this conclusion, investigators sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in active r-axSpA.
Keywords:
乾癬性関節炎患者におけるbimekizumabの症状や障害に対する3年間の効果: BE ACTIVE試験結果
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353
Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.